0.9251
Therapeuticsmd Inc Aktie (TXMD) Neueste Nachrichten
TherapeuticsMD Inc. stock underperforms Thursday when compared to competitors - MarketWatch
TherapeuticsMD Inc. stock outperforms competitors on strong trading day - MarketWatch
TherapeuticsMD (NASDAQ:TXMD) Now Covered by StockNews.com - Defense World
TherapeuticsMD Inc. stock underperforms Monday when compared to competitors - MarketWatch
TherapeuticsMD Full Year 2024 Earnings: US$0.20 loss per share (vs US$0.74 loss in FY 2023) - Yahoo Finance
TherapeuticsMD Reports Improved Financial Performance - TipRanks
TherapeuticsMD Inc. stock underperforms Friday when compared to competitors - MarketWatch
DEADLINE MONDAY: Levi & Korsinsky, LLP Reminds Shareholders of a Class Action to Recover Losses Suffered by Investors in TherapeuticsMD, Inc. and a Lead Plaintiff Deadline of June 19, 2017 -- TXMD - ACCESS Newswire
TherapeuticsMD Inc. (TXMD) reports earnings - Quartz
TherapeuticsMD Reports Reduced Losses and Revenue Growth - TipRanks
TherapeuticsMD Earnings: Net Loss Slashed by $5.4M as Royalty Strategy Pays Off - Stock Titan
TherapeuticsMD Announces Full Year 2024 Financial Results - Business Wire
TherapeuticsMD Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Data at the American College of Obstetricians and Gynecologists 2021 Annual Meeting - Business Wire
TherapeuticsMD Inc. stock rises Wednesday, still underperforms market - MarketWatch
TherapeuticsMD Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
TherapeuticsMD, Inc. to Host Earnings Call - ACCESS Newswire
IMPORTANT INVESTOR ALERT: Lundin Law PC Announces a Securities Class Action Lawsuit against TherapeuticsMD, Inc. and Encourages Investors with Losses to Contact the Firm - ACCESS Newswire
Investor Network: TherapeuticsMD, Inc. to Host Earnings Call - ACCESS Newswire
TherapeuticsMD Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Cosette paying $430M for Mayne's women’s health, dermatology franchise - BioWorld MedTech
How does TXMD’s price to cash per share ratio compare in the market? - US Post News
StockNews.com Begins Coverage on TherapeuticsMD (NASDAQ:TXMD) - Defense World
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):